The β-site APP cleaving enzyme 1 (BACE1) is among the most significant targets for novel drugs to treat Alzheimer's disease (AD) (Huang et al., 2014). The gene discussed is BACE1; the disease is early-onset autosomal dominant Alzheimer disease.